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Abstract
Background: HMG Co-A reductase inhibitors are ubiquitous in our community yet their potential role in age-related macular
degeneration (AMD) remains to be determined.
Methodology/Principal Findings: Objectives: To evaluate the effect of simvastatin on AMD progression and the effect
modification by polymorphism in apolipoprotein E (ApoE) and complement factor H (CFH) genes. Design: A proof of concept
double-masked randomized controlled study. Participants: 114 participants aged 53 to 91 years, with either bilateral
intermediate AMD or unilateral non-advanced AMD (with advanced AMD in fellow eye), BCVA$20/60 in at least one eye,
and a normal lipid profile. Intervention: Simvastatin 40 mg/day or placebo, allocated 1:1. Main outcome measures:
Progression of AMD either to advanced AMD or in severity of non-advanced AMD. Results. The cumulative AMD progression
rates were 70% in the placebo and 54% in the simvastatin group. Intent to treat multivariable logistic regression analysis,
adjusted for age, sex, smoking and baseline AMD severity, showed a significant 2-fold decrease in the risk of progression in
the simvastatin group: OR 0.43 (0.18–0.99), p = 0.047. Post-hoc analysis stratified by baseline AMD severity showed no
benefit from treatment in those who had advanced AMD in the fellow eye before enrolment: OR 0.97 (0.27–3.52), p = 0.96,
after adjusting for age, sex and smoking. However, there was a significant reduction in the risk of progression in the bilateral
intermediate AMD group compared to placebo [adjusted OR 0.23 (0.07–0.75), p = 0.015]. The most prominent effect was
observed amongst those who had the CC (Y402H) at risk genotype of the CFH gene [OR 0.08 (0.02–0.45), p = 0.004]. No
evidence of harm from simvastatin intervention was detected.
Conclusion/Significance: Simvastatin may slow progression of non-advanced AMD, especially for those with the at risk CFH
genotype CC (Y402H). Further exploration of the potential use of statins for AMD, with emphasis on genetic subgroups, is
warranted.
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Introduction
The possible use of HMG Co-A reductase inhibitors, or statins,
to slow AMD progression, has been considered for some time.
Their pleiotropic actions, such as their lipid-lowering and anti-
inflammatory actions, could impact on the underlying pathological
changes involved in AMD pathogenesis.[1,2] An inverse associ-
ation between the use of statins and AMD development has been
reported in a number of retrospective [3–6] and prospective [7]
studies, including our own,[4] as well as in a meta-analysis of eight
studies.[8] However, other studies failed to detect similar
associations [9–16] or even found a harmful effect of long-term
simvastatin intake, with increased hazard rate for developing
exudative AMD.[17] The need for a prospective randomized
controlled trial (RCT) that could address the potential benefits of
statins in AMD was highlighted in recent reviews, including a
Cochrane review.[18,19] Finding a safe and effective intervention
to slow progression of AMD becomes more urgent as our
population ages and the possibility that one may already exist
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within our armamentarium would significantly hasten its intro-
duction if it were found to be effective.
Our first objective was to determine if there is any potential
efficacy signal of HMG Co-A reductase inhibitor ‘simvastatin’ on
the overall progression of AMD, either to advanced disease or to a
greater severity of early stage disease. The second aim was to
investigate the possible influence of genetic variants of the
complement factor H (CFH) or apolipoprotein E (APOE) genes
on efficacy of simvastatin intervention. Our hypotheses were that
simvastatin would slow down AMD progression, and that this
effect could be more prominent at different AMD stages or in
genetically different subgroups. This study also conducted
surveillance of potential harm from simvastatin in people whose
lipid profile would not trigger the use of lipid-lowering medications
for the prevention of cardiovascular disease.
Materials and Methods
Study Design
The design and methodology of this study has been described
previously.[20] Briefly, this was a proof-of-concept, randomized,
placebo-controlled (allocation ratio 1:1), double-masked, three
year study of simvastatin, 40 mg daily, in participants with non-
advanced AMD in at least one eye, considered at high risk of
progression towards advanced AMD. Participants were recruited
from studies on the natural history of AMD or from medical
retinal clinics in Melbourne. The study was conducted at the
Centre for Eye Research Australia (CERA), University of
Melbourne, with the examination sites located at the Royal
Victorian Eye and Ear Hospital (RVEEH) and the Caulfield
General Medical Centre. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Ethics Statement
The project was approved by the Research and Ethics
Committee of the RVEEH, undertaken according to the Helsinki
Declaration for the research on humans and registered with
the Australian New Zealand Clinical Trials Registry (ACTRN
12605000320651, http://www.anzctr.org.au/). Written informed
consent was obtained from all participants prior to entry into the
study.
Recruitment
This study was specifically designed to enrol patients at high risk
of AMD progression. Eligibility criteria required that participants
have at least 1 large druse (.125 um) or extensive intermediate
drusen (63–125 um) with pigment change (intermediate
AMD)[21] in both eyes, or advanced AMD [choroidal neovascu-
larization (CNV) or geographic atrophy [GA]) in one eye and any
non-advanced AMD features in the study eye. A visual acuity of
20/60 or better in the study eye, a blood lipid profile that did not
meet the criteria of the National Heart Foundation of Australia
guidelines for treatment with a lipid lowering agent [22,23] and
absence of confounding ophthalmological diseases such as
glaucoma, diabetic retinopathy or advanced cataract that could
interfere with retinal photographic and functional assessments
were also required.[20]
Study Examinations
Prior to randomization, a standard eye examination was
performed, including measurement of best corrected visual acuity
(BCVA), a dilated slit lamp examination with grading of lens
opacities, digital macular photography using a Canon CR6-45NM
Non-Mydriatic Retinal Camera (Saitama, Japan) and a variety of
retinal visual function tests. Baseline assessment also included
questionnaires on demographics, general medical history, dietary
intake, medications, ethnic origin, and family history of AMD.
Blood samples were collected to test for liver function, lipid profile,
C-reactive protein levels, and genetic polymorphisms.
Biannual follow-up examinations were conducted for three
years after randomization. At each review visit, participants
underwent a full eye examination and blood tests. If clinically
indicated, fluorescein angiography was undertaken to exclude/
confirm CNV. Participants with confirmed CNV were subse-
quently managed in the retinal clinic at RVEEH.
Treatment allocation
Participants were randomly assigned to receive 40 mg of
simvastatin or placebo in tablets of identical appearance and taste
(prepared by MSD AUSTRALIA [Merck Sharp & Dohme
(Australia) Pty Ltd], NSW, Australia). Randomization was
performed by a biostatistician using permuted blocks of randomly
varying size.[20] The allocation list was stored at a remote site.
The study staff, the participants, and data analysts were masked to
treatment allocation until the analysis was finalised. The hospital
pharmacist packed the medication into identical containers
according to the randomization code. The sequentially numbered
containers were allocated to the participants by the study
coordinator in order of enrolment.
Compliance and adverse events
Participants who were advised by their treating physician to
start cholesterol lowering medication during the course of the
study were asked to start 40 mg of simvastatin and were allocated
‘off protocol’ status. Compliance was determined using self-
reporting, counting unused tablets and by measuring each
subject’s lipid profile every 6 months. Liver function tests were
conducted at each review. Adverse events were reviewed by a
safety monitoring committee with severe adverse events reported
to the ethics committee. The trial would be stopped if rates of
drug-related adverse events were found to be significantly higher
in the active treatment group.
Assessment of AMD status
Fundus examination and photography were performed at each
visit. Digital images of each macula were graded according to the
International Classification and Grading System for AMD by two
trained graders, masked to treatment allocation.[24] Grading was
conducted using the ‘OptoMize PRO’ software from Digital
Healthcare Image Management System (Digital Healthcare Ltd
(DH), Cambridge, UK). Each macula was graded within a
6000 um diameter grid centred on the fovea for type, size,
location, number, centrality and area covered by AMD features.
Thus, drusen type (intermediate, soft distinct or soft indistinct),
number (1–9, 10–19, 20 or more), size (.63 m, .125 m, .175 m,
.250 m), centrality (fovea, central, middle, outer subfields or
outside the grid), and area covered (,10%,,25%,,50%,.50%
of the areas delineated by the central, middle and outer circles of
the grid) were determined. For pigment changes, differences in
size, centrality, and area covered were assessed. Advanced AMD
was defined as presence of either CNV or GA. CNV was
confirmed on angiography and GA was defined as an area of
hypopigmentation .175 mm with a choroidal vessel in its base on
colour photography. Fundus autofluorescence and Optical
Coherence Tomography images were not available when this
study was conducted. Any discrepancies in grading were resolved
through adjudication by senior clinicians (LR, RG). Kappa for
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inter-grader and intra-grader agreement for the study graders
ranged from 0.64 to 0.76 and from 0.60 to 1.00, respectively and
has been published elsewhere.[25]
Outcome Measures
Primary outcome was progression of non-advanced AMD to
either advanced AMD or higher severity scores of non-advanced
AMD. The safety of the use of simvastatin in people whose lipid
profile did not warrant intervention with a lipid lowering agent
was assessed by analysis of adverse events.
Assessment of AMD progression
Progression was determined by comparison of AMD severity
based on detailed AMD grading and confirmed by a masked side-
by-side comparison of the baseline and the last follow-up images.
Cases of disparity were reviewed with additional information from
clinical examination and adjudicated where necessary.
AMD severity in each eye at baseline and at follow-up visits was
assessed using a previously published [26,27] 6-level severity scale
based upon fundus features within a 6000 mm circle centred on the
fovea, with higher levels indicating more severe disease. The
severity scale was: Level 1 - hard drusen (,63 mm) only; Level 2 –
intermediate drusen (64–125 mm) or hyperpigmentation only;
Level 3 – large (.125 mm) soft drusen, without pigment change or
intermediate drusen with pigment change; Level 4 – large soft
drusen AND pigment change; Level 5 – GA within 3000 mm of
the fovea; Level 6 – CNV. All participants with bilateral non-
advanced AMD had a severity Level of 3 or above in both eyes at
baseline, correspondent to ‘intermediate AMD’ in the Beckman
classification of AMD.[21] Change of AMD status to a more
severe level on this scale was considered as progression. Where one
eye progressed to GA and the other eye progressed to CNV, we
classified the participant as ‘progressed to CNV’ in ‘by person’
analysis (one case in each group).
To allow for smaller increments in AMD status to be considered
as progression, those cases where there was an increase of 2 or
more steps within the specific levels were also considered to have
progressed. To assess this change we considered an increase in
size, total number, area occupied by a lesion or movement to a
more central location, as the within-level progression. Individuals
who had a one step worsening in at least 2 characteristics were also
classified as progressed (Table 1). Regression of early AMD
features was also recorded.
Masked side-by-side comparisons of baseline and 36 months
visit images were performed independently for the whole sample
by four graders, so that each eye was determined to be either the
same, better, or worse in severity at follow-up when compared to
baseline. If there was any doubt as to whether change has
occurred, the images were scored as ‘same’. The side-by-side
results were then matched with the results from the detailed
grading of macular characteristics and discrepancies were resolved
by consensus using all available clinical information. The side-by-
side comparison allowed for a ‘whole picture’ approach in
identifying small changes in AMD status that might not have
been detected otherwise.[28]
Genetic analysis
Genomic DNA was isolated from venous blood leukocytes using
a standard phenol/chloroform extraction procedure. APOE
genotyping was performed by multiplex high-resolution amplicon
melting (TrendBio Pty Ltd, Melbourne, Australia).[29] Two
primer pairs were designed to encompass 2 sites at amino acid
positions 112 (site A) and 158 (site B) of the APOE gene. A
sequence variant of c.526C.T for ???2 allele is present at site A
(GenBank reference sequence NM_000041.2) or c.388T.C for
???4 allele is present at site B (reference sequence NM_000041.2)
resulting in either a cysteine or arginine residue respectively. CFH
genotyping for rs1061170 (Y402H) and rs2274700 SNPs was
performed using the MassARRAYH platform (SEQUENOM) as
previously described.[30]
Statistical Analysis
Primary analysis was done on intent to treat basis and utilized
logistic regression analysis to assess the effect of simvastatin on
AMD progression, after adjusting for pre-specified co-variables of
age, sex, smoking status, and also status of disease in the fellow eye
(intermediate or advanced). Analysis was done ‘by person’ and
used the data from the eye showing greatest progression. If one eye
of a person worsened and the other eye showed improvement, the
person was classified as having progressed. The latest available
observation from those participants who finished the study earlier
than 36 months was carried forward.
Secondary analyses included on protocol, cross-over (actual
simvastatin use), and genetic analyses. In cross-over analysis, the
participants who started on placebo and were then commenced on
simvastatin by their general practitioner were analysed as being in
the active treatment group. Additionally, as two treatment arms,
despite the randomization, were uneven in proportion of
participants with advanced disease in one eye (higher in the
simvastatin group), we performed a post hoc analysis stratified by
AMD severity in the fellow eye.
To address our second aim, we pre-planned to determine the
modifying effect of apolipoprotein E (ApoE) gene single nucleotide
polymorphisms (SNPS) on treatment efficacy, as the impetus for
this study on simvastatin was based on our previous research that
implicated involvement of the ApoE gene (a cholesterol pathway
gene) in AMD development.[31,32] Additionally, given the
evidence for the association of AMD and its progression with
Table 1. Macular characteristics used to determine severity in non-advanced age-related macular degeneration.
Macular Features Maximal size (mm) Number*
Most central location (distance
from the fovea in mm)
Area affected in each location
(as per column 4)
Intermediate drusen* = 63,125 0 Further than 3000 0
Soft distinct drusen = 125,250 1 to 9 1500 to 3000 ,10%
Soft indistinct drusen = 250 10 to 19 500 to 1500 ,20%
Hyperpigmentation 20 or more ,500 ,50%
Hypopigmentation Foveal .50%
*Category ‘Number’ is related to drusen only.
doi:10.1371/journal.pone.0083759.t001
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complement factor H (CFH) gene, an exploration of the
moderating effect of different genetic variants of the CFH gene
on simvastatin treatment was also included in the statistical
analysis plan.
The possible moderating influence of genotype on the effect of
simvastatin was assessed through the tests of multiplicative
interactions between treatment type (simvastatin versus placebo)
and the at risk genotypes. Interactive effects were tested using a
2-stage sequential logistic regression model, with treatment type
and genotype entered into the model at stage 1 and interaction
between these 2 variables added in stage 2. Where statistically
significant interaction suggested a moderating influence of
genotype on the effect of simvastatin, we conducted further
analysis of treatment outcome in placebo and simvastatin groups,
stratified by genotype.
Adverse events and compliance with the assigned treatment of
simvastatin and placebo were assessed using x2 tests. Lipid profiles
were compared between baseline and latest available follow-up
measurement within a 36 months period using paired-samples
t-tests, and differences in total cholesterol, HDL-C, LDL-C, and
triglyceride levels between the two treatment groups at the end of
follow-up were assessed using t-tests for independent samples.
Sample size and study power
The natural history of AMD is that its severity in non-advanced
features increases gradually over many years, ultimately progress-
ing to sight-threatening advanced AMD. Phase 3 trials require
many thousands of participants to be studied over many years to
determine efficacy in reducing the risk of progression to advanced
AMD [33,34] This proof of concept study aimed to determine,
with smaller numbers, if there was any efficacy signal in smaller
degrees of progression so that we were interested not only in
progression to advanced AMD but also in progression within the
earlier stages of disease. Therefore, we calculated the sample size
based on the previously observed rates of progression that included
both the progression to advanced AMD and the estimates of the
gradual increase in non-advanced AMD severity.[21]
The participants enrolled in the study presented a high risk of
progression due to having either bilateral drusen.125 mm with or
without pigmentary change, or multiple intermediate drusen and
pigmentary change (12% to 50% five-year risk of progression to
advanced AMD) or unilateral advanced AMD in one eye and any
non-advanced AMD features in the other eye (35% to 53% five-
year risk of progression to advanced AMD in the second
progressing eye).[35] In addition, we also took as progression an
increase in severity within non-advanced disease. For example, the
risk of bilateral medium sized drusen (63 to 125 mm) becoming
large drusen has been recently identified and reported as 40% in 3
years (Figure 5 from Ferris et al, 2013).[21] Given that our criteria
for progression included small stepped increases in severity within
non-advanced stages of disease, such as increases in size, number,
area and centrality of drusen, we estimated that 50% of the study
cohort will progress over 3 years according to the criteria outlined
in this and other papers. [26,27,36]
To detect a 50% reduction in progression of disease (from 50%
to 25%), with power of 80% and alpha= 0.05, we needed to study
58 subjects in each arm. Sample size calculations were performed
with the PS - Power and Sample Size Calculation software.[37]
The data were analysed using SPSS-18 statistical package for
Windows (PASW Statistic 18, SPSS Inc, Chicago, USA). The
Forest plot was constructed using StatsDirect statistical software
version 2.7.9 (9/07/2012, http://www.statsdirect.com/), (Stats-
Direct Ltd, Altrincham, UK).
Results
Baseline characteristics
A total of 114 participants were enrolled and randomized in
2003-2006 and followed up for three years, with 57 randomized to
placebo and 57 randomized to active medication (Figure 1). Mean
age of participants was 74.667.0 years; 77 (68%) were female and
60 (53%) were current or former smokers; 48 (42%) participants
had advanced AMD, either GA or CNV, in one eye at baseline.
Baseline characteristics were similar between the two study
groups, except that the number of participants with unilateral
advanced AMD was twice as large in the simvastatin group
compared to the placebo group (x2 df = 1 = 9.2, p = 0.002). Smoking
was also less prevalent in the placebo group; the difference was
marginally significant (x2 df = 1 = 3.5, p = 0.06) (Table 2).
Association between AMD progression and
simvastatin – total sample
At 3 years follow-up, the total progression of AMD from
baseline was 31/57 (54%) individuals in the simvastatin group and
40/57 (70%) individuals in the placebo group (Table 2). This was
mainly explained by the increased number of participants
worsening in the severity of non-advanced AMD in the placebo
group compared to the simvastatin group (49% vs. 32%,
respectively, Table 3). When progression to advanced AMD was
assessed, there were equal proportions of participants in both
treatment arms: 12/57 (21%) in the simvastatin group (7 to GA
and 5 to CNV) and 12/57 (21%) in the placebo group (9 to GA
and 3 to CNV).
The intent to treat univariate logistic regression analysis showed a
tendency towards reduction of the odds of all AMD progression in
the simvastatin group, although not statistically significant, with
OR 0.51 (95% CI 0.23, 1.09), p = 0.08. In multivariate analysis,
there was a significant reduction in AMD progression in the
simvastatin group compared to the placebo group (OR=0.43
(95% CI 0.18, 0.99), p = 0.047), after adjusting for age, sex,
smoking, and unilateral advanced AMD status at baseline (Table 4
and Figure 2). Similar results were obtained in the cross-over
analysis (adjusted OR=0.47 (95% CI 0.20, 1.09), p = 0.08). In on
protocol analysis, the effect of simvastatin was in the same direction
although less significant (Figure 2).
Stratification by AMD severity at baseline (post hoc
analysis)
Intent to treat multivariate logistic regression analysis, stratified by
baseline severity (presence of unilateral advanced AMD), revealed
no significant effect of simvastatin on AMD progression amongst
those who already had advanced AMD in the fellow eye
(OR=0.97 (95%CI 0.27, 3.52) p= 0.96), after adjusting for age,
sex, and smoking status. However, in the group with bilateral
intermediate AMD at baseline, treatment with simvastatin resulted
in a large reduction in the odds of progression compared to the
placebo group (adjusted OR=0.23 (95%CI 0.07, 0.75) p= 0.015)
(Table 4).
AMD progression by genotype and treatment allocation
Genotyping results were available from 105 participants for the
ApoE gene. The majority of the participants (63%) carried the
???3/???3 genotype and 26% carried at least one at risk ???2 allele
(Table 2); these frequencies are similar to the ones we have
observed previously in a similar population.[38] In relation to
the CFH gene, we conducted separate analyses for the two SNPs
of the CFH gene known to be associated with the risk of
Simvastatin and Age-Related Macular Degeneration
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AMD: rs1061170 (n = 107) and rs2274700 (n= 103). Very few
individuals were homozygous for the T allele at either SNP
(Table 2) which mirrored our previous findings in early AMD
[30], hence they were aggregated with the CT genotype for the
analyses. There was no departure from Hardy-Weinberg equilib-
rium for ApoE or CFH genetic variants (p.0.05).
In the intent to treat analyses we found a significant, 2-fold
reduction in the odds of AMD progression associated with
simvastatin treatment when rs1061170 (Y402H) was included in
the multivariate model, (Table 5) which also included age, sex,
smoking and unilateral advanced AMD. There was an interaction
between simvastatin treatment and the CC genotype at the
Y402H SNP of the CFH gene (p= 0.04), therefore we stratified the
analysis by the Y402H genotypes of the CFH gene (Table 5).
Logistic regression analysis stratified by Y402H genotype showed a
highly significant 12-fold reduction in AMD progression in the
group assigned to simvastatin if they were homozygous for the at
risk C allele at Y402H of the CFH gene [OR=0.08 (95%CI 0.02,
0.45), p = 0.004], but not in the combined group of CT and TT
genotypes (p = 0.74) (Table 5). ApoE genotype did not influence the
effect of simvastatin on AMD progression (p = 0.86) (Table 5).
The analyses presented here are also summarised in Figure 2.
As can be seen, the overall trend is for the direction of the effect to
consistently favour simvastatin.
Compliance with the study medication
Overall, 86/114 (75%) individuals, equally distributed between
the two groups, were estimated to have consumed over 75% of
their allocated tablets. At the three year follow-up visit, 41 (72%) of
the simvastatin group and 40 (70%) of the placebo group either
remained on their assigned medication and participated in the
biannual reviews or had ceased the study treatment because they
had reached advanced AMD in both eyes. Seven (12%)
participants from the placebo group commenced cholesterol
lowering medications prescribed by their physician due to an
abnormal lipid profile (Figure 1).
Figure 1. Flowchart of study participation.
doi:10.1371/journal.pone.0083759.g001
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Nine participants did not attend any follow-up examinations
(5 due to poor health, 3 for personal reasons, 1 from an adverse
reaction to the drug in the simvastatin group, 1 case was enrolled
incorrectly, having advanced AMD in both eyes, and in one
additional case, epiretinal membranes developed in both eyes,
which precluded accurate photo-assessment of AMD progression.
For these 11 records, baseline data on AMD status were carried
forward and used as the outcome in intent to treat analyses.
Indirectly, compliance was also assessed through comparison of
lipid profiles at baseline and the latest follow-up within 36 months.
This information was available for 113 participants: 57 from the
placebo and 56 from the simvastatin group. There was a
significant difference between the two groups in mean changes
in the levels of total cholesterol, LDL-cholesterol, and triglycerides
between baseline and the latest follow-up tests, with lowering of
the lipid levels by 20% to 25% in the simvastatin group and no
significant changes in the placebo group. Both groups had a
lowering of HDL cholesterol levels, with no difference between the
groups (Table 6).
Adverse events
Administering simvastatin to a cohort that would not have
warranted lipid-lowering medications as a result of their lipid
profile is not well studied and required surveillance of harm. In this
study, we used both liver function tests and passive surveillance of
adverse events that the study participants had spontaneously
reported during follow-up assessments. The information on
specific symptoms of possible side effects of statins, such as muscle
pain and weakness, rash, mild and temporary headache, was
provided to the study participants, and the importance of
reporting such symptoms was explained at the time of consenting
to the study.
Overall, 64 people reported at least one adverse event within
the 36 months of follow-up, 25/57 (44%) in the simvastatin group
Table 2. Baseline characteristics of placebo and simvastatin study groups.
Participant characteristics Placebo n=57 Simvastatin n=57
Age, mean (SD), years 74.4 (6.4) 74.8 (7.5)
Women, No. (%) 38 (66.7) 39 (68.4)
Ever smoked, No. (%) 25 (43.9) 35 (61.4)
Advanced AMD in one eye, No. (%) 16 (28.1) 32 (56.1)
Supplements intake, No. (%) 38 (66.7) 33 (57.9)
History of cardiovascular disease, No. (%) 11 (19.3) 5 (8.8)
History of hypertension, No. (%) 23 (40.4) 18 (31.6)
Total cholesterol level, mean (SD), mmol/L 5.71 (0.78) 5.63 (1.06)
HDL Cholesterol level, mean (SD), mmol/L 1.86 (0.45) 1.78 (0.44)
LDL Cholesterol level, mean (SD), mmol/L 3.34 (0.66) 3.27 (0.97)
Triglycerides level, mean (SD), mmol/L 1.10 (0.39) 1.25 (0.51)
ApoE genotype, No. (%)
???2/???3 10 (18.9) 12 (23.1)
???2/???4 3 (5.7) 2 (3.8)
???3/???3 33 (62.3) 33 (63.5)
???3/???4 7 (13.2) 5 (9.6)
CFH rs1061170 genotype, No. (%)
CC 23 (42.6) 22 (41.5)
CT 24 (44.4) 27 (50.9)
TT 7 (13.0) 4 (7.5)
CFH rs2274700 genotype, No. (%)
CC 30 (57.7) 36 (69.2)
CT 22 (42.3) 15 (28.8)
TT 0 (0.0) 1 (1.9)
doi:10.1371/journal.pone.0083759.t002
Table 3. AMD progression by treatment group.
Placebo Simvastatin
At risk of progression by person, No. 57 57
Progressed total, No. (%) 40 (70.2) 31 (54.4)
Progressed to advanced AMD, No. (%) 12 (21.1) 12 (21.1)
Progressed, but not to advanced AMD,
No. (%)
28 (49.1) 18 (31.6)
At risk of progression by eye, No. 97 82
Progressed total, No. (%) 58 (59.8) 40 (48.8)
Progressed to advanced AMD, No. (%) 16 (16.5) 14 (17.1)
Progressed to non-central GA, No. (%) 7 (7.2) 5 (6.1)
Progressed to central GA, No. (%) 6 (6.2) 4 (4.9)
Progressed to CNV, No. (%) 3 (3.1) 5 (6.1)
Progressed, but not to advanced AMD,
No. (%)
42 (43.3%) 26 (31.7)
doi:10.1371/journal.pone.0083759.t003
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and 39/57 (68%) in the placebo group (x2 df = 1 p = 0.008). Major
illnesses were reported by 7 individuals in the simvastatin group
and 15 individuals in the placebo group, and there was 1 death in
the placebo group. Muscle aches, a recognized side effect of
statins, were reported in 7 participants: 2 on placebo and 5 on
simvastatin. As a result, 4 withdrew from the study (1 placebo and
3 simvastatin), 1 (placebo) stopped taking the assigned tablets and
continued in an off protocol mode and 2 participants (both
simvastatin) continued with the randomized treatment, as the
symptoms settled. Two participants (one in each treatment group)
were diagnosed with acute hepatitis. Otherwise, none of the
participants had abnormal liver function tests that necessitated
stopping medication.
In total, there was an absence of evidence of harm from using
simvastatin in the dose of 40 mg daily.
Discussion
This study reports the results from the first longitudinal proof-
of-concept double-masked randomized placebo-controlled trial
exploring the effect of the HMG Co-A reductase inhibitor,
simvastatin, on slowing the progression of AMD. Our results
indicate that dose of 40 mg daily was well tolerated in people with
normal lipid profiles and that simvastatin appears to have a role in
slowing progression of bilateral intermediate AMD. In those who
had already developed advanced AMD in their fellow eye, we did
not detect a beneficial effect for the eye with non-advanced AMD.
The effect of simvastatin was more pronounced in those who were
homozygous for the at risk C allele of the Y402H SNP of the CFH
gene.
Almost all participants in this study had at least one C allele at
Y402H, which is consistent with many AMD studies, including
our own.[30] The reference group consisted mainly of individuals
who were heterozygous at this SNP. However, as specific targeting
of genetically predisposed individuals was not a factor in initial
recruitment, this should not be considered problematic. The
detection of the benefit of simvastatin predominantly amongst
those homozygous for the at-risk CC genotype of Y402H of the
CFH gene suggests that in future studies, genotype should be taken
Figure 2. Forest plot of odds ratios (95% confidence intervals) for the effect of simvastatin on AMD progression from different
models of the analysis.
doi:10.1371/journal.pone.0083759.g002
Table 4. Logistic regression analysis of simvastatin effect on AMD progression.
Type of analysis Unadjusted estimates Adjusted estimates*
OR 95% CI p-value OR 95% CI p-value
Intent to treat, total sample (n = 114) 0.51 0.23, 1.09 0.08 0.43 0.18, 0.99 0.047
On protocol only, total sample (n = 81) 0.78 0.29, 2.08 0.62 0.51 0.17, 1.54 0.23
Actual use of simvastatin (cross over), total sample (n = 114) 0.55 0.25, 1.20 0.13 0.47 0.20, 1.09 0.08
Intent to treat, stratified by AMD status:
Subset of intermediate bilateral AMD (n = 66) 0.34 0.12, 0.96 0.04 0.23 0.07, 0.75 0.015
Subset of non-advanced AMD in one eye and advanced AMD
in the fellow eye (n = 48)
0.88 0.26, 3.01 0.83 0.97 0.27, 3.52 0.96
*Adjusted for age, sex, smoking, and unilateral advanced AMD.
doi:10.1371/journal.pone.0083759.t004
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into consideration when assessing the potential effect of statins in
AMD. Previous studies examining the effect of statins in AMD
may have missed a beneficial effect by not stratifying their analysis
by genotype.
Statins, initially used as cholesterol-lowering agents,[39,40] have
a variety of well recognized modes of action, some of which may
benefit individuals presenting with AMD. By binding to HMG-
CoA reductase’s active site, statins inhibit hepatic cholesterol
biosynthesis and reduce serum levels of low density lipoprotein
cholesterol (LDL-C). The non-lipid-related actions of statins
include improvement of endothelial functions, decrease of LDL
oxidation, as well as reduction of inflammation and angiogenesis –
all potentially important factors in AMD pathogenesis.[1,2]
Our finding of a significant slowing of AMD progression due to
simvastatin treatment (OR 0.43 (95% CI 0.18, 0.99), p = 0.047)
was similar to the results obtained from a meta-analysis of case-
control and cohort studies, where the pooled relative risk (RR) of
developing AMD for all studies was 0.74 (95% CI 0.55, 1.00).[8]
The prospect that there may be a differential effectiveness of
simvastatin according to genotype is of great interest. It is not the
first time that statins have been shown to work differentially in
different populations. Rosuvastatin reduced the risk of major
cardiovascular events in the group with no cardiovascular risk
factors, apart from an elevated CRP, but it was most effective in
those who showed a decreased CRP post statin. [41,42]. It is
possible that the lack of stratification by genotype has led to
inconsistent results in previous studies investigating the association
between statins and AMD. [3–16]
Statins are the most prescribed and used drugs in Australia
[43,44] and other Western countries and their use has increased
within the last 10 years. The recent suggestion that there has been
a decrease in AMD incidence in later birth cohorts raises the
Table 5. AMD progression by treatment allocation and genotypes of the CFH and APOE genes.
Unadjusted estimates Adjusted estimates*
OR 95% CI p-value OR 95% CI p-value
rs1061170 (Y402H) of the CFH gene
Simvastatin 0.46 0.20, 1.03 0.06 0.40 0.16, 0.97 0.04
CC genotype of the rs1061170 1.09 0.48, 2.49 0.83 1.13 0.48, 2.66 0.78
Interaction term ‘‘CC rs1061170 by simvastatin’’ 0.024 0.04
Stratification by rs1061170 (Y402H) genotype of the CFH gene
1. Effect of simvastatin in the subset of participants with CC genotype 0.13 0.03, 0.55 0.01 0.08 0.02, 0.45 0.01
2. Effect of simvastatin in the subset of participants with CT or TT genotype 1.00 0.35, 2.83 1.00 0.82 0.25, 2.66 0.74
rs2274700 of the CFH gene
Simvastatin 0.49 0.21, 1.12 0.09 0.43 0.17, 1.07 0.07
CC genotype of the rs2274700 1.28 0.55, 3.02 0.57 1.23 0.50, 3.01 0.65
Interaction term ‘‘CC rs2274700 by simvastatin’’ 0.21 0.17
ApoE genotype
Simvastatin 0.49 0.22, 1.12 0.09 0.46 0.19, 1.14 0.09
ApoE genotypes (at least one ???2 vs. no ???2) 1.44 0.58, 3.60 0.43 1.41 0.53, 3.75 0.49
Interaction term ‘‘???2-containing ApoE genotypes by simvastatin’’ 0.88 0.86
Note: Interactions between genotype and simvastatin were tested in a sequential regression model, with treatment group and genotype entered in the first stage and
interaction between these two variables entered in the second stage. Coefficients shown are from stage 1 model for the treatment group and genotype variables and
from stage 2 for interactions.
*Adjusted for age, smoking, sex and unilateral advanced AMD.
doi:10.1371/journal.pone.0083759.t005
Table 6. Lipid levels at baseline and follow-up by treatment allocation.
Test Treatment Baseline Follow-up P value* P value**
Total Cholesterol, Mean (SD), mmol/L Placebo 5.71 (0.78) 5.66 (0.80) 0.53 0.001
Simvastatin 5.63 (1.06) 4.47 (0.85) 0.01
HDL Cholesterol, Mean (SD), mmol/L Placebo 1.86 (0.45) 1.75 (0.43) 0.01 0.56
Simvastatin 1.78 (0.44) 1.70 (0.44) 0.02
LDL Cholesterol, Mean (SD), mmol/L Placebo 3.34 (0.66) 3.36 (0.66) 0.76 0.001
Simvastatin 3.27 (0.97) 2.31 (0.69) 0.01
Triglycerides, Mean (SD), mmol/L Placebo 1.10 (0.39) 1.18 (0.56) 0.12 0.001
Simvastatin 1.25 (0.51) 1.00 (0.37) 0.01
*P value from paired samples t-test, comparing baseline and follow-up measurements in each treatment group.
**P value from independent samples t-test comparing the differences (baseline level minus follow-up level) between the two treatment groups.
doi:10.1371/journal.pone.0083759.t006
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possibility that the recent wide spread use of statins to lower
cholesterol levels may have contributed to the decline in AMD
incidence.[45]
Recruiting participants into this study was extremely challeng-
ing, as many potentially eligible individuals with AMD were
already taking statins or had lipid profiles where lipid-lowering
agents were recommended. Whilst our study provides some
support for a potential role for statins in AMD, a larger RCT
would be required to provide a definitive result. With criteria for
recommending statin use having widened in recent years, it will be
even more difficult to attempt a RCT of statin use in AMD. It
would, however, be possible to search for corroborating evidence
by returning to the large population-based studies on AMD and
repeat analyses, stratifying by genetic risk and the presence of
unilateral advanced AMD.
The strengths of this study include its prospective, randomized,
double masked design, the high rate of compliance, detailed
grading of the macular photographic images, side-by-side assess-
ment of baseline and follow-up images and the availability of
angiographic findings to confirm CNV. The associations of AMD
progression with age, smoking, and CFH polymorphism in this
study were all consistent with other studies, indicating the
similarities of our study cohort to the broader AMD-affected
population. The limitations of the study are its relatively small
sample size, the relatively high attrition rate, and a slightly higher
number of participants in the simvastatin group who had no
follow-up data. The use of only a moderate dose of simvastatin,
and only three years of follow-up may also have limited the
magnitude of the observed effect.
The relatively small sample size did not allow us to fully assess
the effects of simvastatin on the incidence of advanced AMD. A
moderate dose of simvastatin (40 mg per day) was chosen to
minimize the risk of adverse events in a cohort of patients with
normal lipid profiles; however there is a possibility that the effect
could have been greater with a higher dose of simvastatin. As
AMD progresses slowly, a longer follow-up could have provided
more information on long-term effectiveness of simvastatin use in
AMD. The observational Blue Mountain Eye Study was unable to
detect any association of statins with AMD progression at a 5 year
follow-up, [11] but after 10-years they were able to show that
statins appeared to be associated with slowing the development of
soft drusen.[7]
Although randomization was used to reach comparability
between study arms, this randomization resulted in an imbalance
in the distribution of smoking and advanced AMD in one eye at
baseline between the two treatment groups. This imbalance meant
that those most likely to progress (smokers and the unilateral
advanced disease) were over represented in the treatment group.
Although theoretically this made it more difficult to show a
beneficial effect of the intervention, a protective association was
still found.
In all sub-analyses the effect consistently fell on the side of
favouring simvastatin. This is re-assuring and makes the chance
association less probable. However given the sample size, the
results stratified by the genotypes should not be overstated and
further research into the use of statins in AMD, particularly
profiled by genotype, would be invaluable. Statins are drugs with a
well-defined safety profile and are currently taken by millions of
people worldwide. If truly beneficial in slowing progression of
AMD, their implementation would be low risk and rapid. The
results presented here strongly indicate the importance of further
determining the potential role of statins in slowing progression of
AMD towards vision loss.
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